Spero sought approval of tebipenem on the strength of a phase 3 trial – ADAPT-PO – which showed that the drug was equivalent to standard care with intravenous ertapenem in patients with cUTI ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...

Of these alternative choices, we recommend ertapenem owing to our ability to dose it once a day. Finally, for those women with an immediate hypersensitivity to penicillin, we would recommend the ...

Objective: No prospective trials have been carried out comparing antibiotic treatment alone with primarily surgical treatment in patients with diabetes and foot osteomyelitis. The aim of the ...